Heartland Advisors Inc. Acquires New Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Heartland Advisors Inc. purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 155,850 shares of the biotechnology company's stock, valued at approximately $1,674,000. Heartland Advisors Inc. owned approximately 0.18% of Anavex Life Sciences as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Orion Capital Management LLC lifted its holdings in Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock worth $65,000 after buying an additional 10,000 shares during the last quarter. PVG Asset Management Corp bought a new position in Anavex Life Sciences during the third quarter worth $74,000. BNP Paribas Financial Markets boosted its holdings in Anavex Life Sciences by 97.0% in the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock worth $86,000 after purchasing an additional 7,421 shares during the period. Erste Asset Management GmbH acquired a new position in Anavex Life Sciences in the third quarter worth $102,000. Finally, Berkshire Money Management Inc. bought a new stake in Anavex Life Sciences during the fourth quarter valued at $107,000. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Stock Performance

Shares of AVXL traded up $0.62 during midday trading on Wednesday, hitting $8.64. 587,116 shares of the stock traded hands, compared to its average volume of 1,250,912. The business's 50 day moving average price is $8.96 and its two-hundred day moving average price is $8.37. The firm has a market capitalization of $734.95 million, a PE ratio of -15.71 and a beta of 0.94. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $14.44.

Remove Ads

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. As a group, equities research analysts forecast that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a report on Wednesday, February 12th. HC Wainwright restated a "buy" rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.